Results 1 to 10 of about 45,216 (237)

Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression [PDF]

Infectious Agents and Cancer, 2021
Background HBV promotes cell survival by upregulating the expression of the cellular inhibitor of apoptosis protein 2 (cIAP2), however whether it is involved in HBV-induced sorafenib resistance in liver cancer remains unclear.
Shouhua Zhang, Nuoya Li, Yanling Sheng, Wen Chen, Qiangliang Ma, Xin Yu, Jianping Lian, Junquan Zeng, Yipeng Yang, Jinlong Yan   +9 more
doaj   +2 more sources

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2 [PDF]

Biology, 2023
Sorafenib, a kinase inhibitor, has shown promising therapeutic efficacy in a subset of patients with acute myeloid leukemia (AML). However, despite its clinical effectiveness, sorafenib resistance is frequently observed in clinical settings, and the ...
Xi Xu, Weiwei Ma, Guo Qiu, Li Xuan, Chong He, Tian Zhang, Jian Wang, Qifa Liu   +7 more
doaj   +2 more sources

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma [PDF]

Frontiers in Oncology, 2021
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Sorafenib is approved by the U.S. Food and Drug Administration to be a first-line chemotherapy agent for patients with advanced HCC.
Xinyao Hu, Xinyao Hu, Hua Zhu, Yang Shen, Yang Shen, Xiaoyu Zhang, Xiaoyu Zhang, Xiaoqin He, Xiaoqin He, Ximing Xu, Ximing Xu   +10 more
doaj   +2 more sources

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1

Signal Transduction and Targeted Therapy, 2020
Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we
Wei Zheng, Kirill Gorshkov, Qiming Sun
exaly   +2 more sources

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway [PDF]

Cell Death and Disease
Sorafenib is an antiangiogenic and antiproliferative chemotherapeutic drug that plays a crucial role in the treatment of patients with advanced hepatocellular carcinoma (HCC). However, resistance to sorafenib greatly limits its therapeutic efficacy. This
Ruimei Ren, Shan Zhang, Zhan Peng, Xiaomeng Ji, Hao Song, Qiuxiao Wang, Xiangyin Sun, Huiyu Wang, Yinying Dong   +8 more
doaj   +2 more sources

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

Signal Transduction and Targeted Therapy, 2021
The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months.
Junhao Zheng, Yifan Wang, Xiao Liang
exaly   +2 more sources

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma

iScience, 2023
Summary: Sorafenib induces ferroptosis, making it a useful treatment against advanced liver hepatocellular carcinoma (LIHC). However, sorafenib resistance is extremely common among LIHC patients.
Mengxing Cai, Jingwen Luo, Chunxiu Yang, Xiaopeng Yang, Cheng Zhang, Lixin Ma, Yibin Cheng   +6 more
doaj   +2 more sources

Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis

Journal of Experimental & Clinical Cancer Research, 2020
Background The identification of novel targets for recovering sorafenib resistance is pivotal for Hepatocellular carcinoma (HCC) patients. Mitophagy is the programmed degradation of mitochondria, and is likely involved in drug resistance of cancer cells.
Hong Wu, Tao Wang, Yiqiang Liu, Xin Li, Senlin Xu, Changtao Wu, Hongbo Zou, Mianfu Cao, Guoxiang Jin, Jinyi Lang, Bin Wang, Baohua Liu, Xiaolin Luo, Chuan Xu   +13 more
doaj   +2 more sources

SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma [PDF]

Neoplasia: An International Journal for Oncology Research
Background: Drug resistance prominently hampers the effects of sorafenib in hepatocellular carcinoma (HCC). Epigenetics play important roles in drug resistance.
Shanshan Wang, Weicheng Wu, Zhen Shi, Mei Bin, Fengwei Zhang, Long Cai, Kaiqing Lin, Zhihui Li   +7 more
doaj   +2 more sources

Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation [PDF]

Frontiers in Pharmacology
BackgroundCurcumol, a bioactive sesquiterpenoid extracted from traditional Chinese medicine (TCM), has demonstrated potential in overcoming tumor drug resistance.
Ni Zhang, Xinchen Tian, Fen Liu, Xiaohan Jin, Xiaohan Jin, Jiaqi Zhang, Lingli Hao, Shulong Jiang, Shulong Jiang, Qingbin Liu, Qingbin Liu   +10 more
doaj   +2 more sources